Method of treatment of androgen-related diseases

Details Method of treatment of androgen-related diseases Method of treatment of androgen-related diseases

1992-10-19

1994-12-13

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 16, 514 17, 514114, 514177, 514800, 540 4, 540 5, 540 22, 540 23, 552515, 552522, 552540, 552304, A61K 3702, A61K 3743, C07J 4100

Patent

active

053729960

ABSTRACT:
A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione (.DELTA..sup.4 -dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.

REFERENCES:
patent: 4024248 (1977-05-01), Konig et al.
patent: 4055641 (1977-10-01), Benson et al.
patent: 4100274 (1978-07-01), Dutta et al.
patent: 4118483 (1978-10-01), Konig et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191759 (1980-03-01), Johnston et al.
patent: 4235893 (1978-05-01), Brodie
patent: 4329364 (1982-05-01), Neri et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4472382 (1984-09-01), Labrie et al.
patent: 4474813 (1984-02-01), Neri et al.
patent: 4659516 (1987-04-01), Bowler
patent: 4659695 (1987-04-01), Labrie
patent: 4822528 (1989-04-01), Columbo et al.
patent: 5053403 (1981-10-01), Orenteich et al.
patent: 5064813 (1991-11-01), Labrie
Grant and Hackh's Chemical Dictionary (New York, McGraw-Hill, 1987) p. 14.
Klingmuller et al., J. Steroidal Biochem. 20(68), 1395 1984.
Labrie et al., J. Steroidal Biochem. 31(1) 61-64, 1988.
Schallu et al cancer treatment Reports 68(1) 281-289.
Redding, Proc. Natl. Acad. Sci USA 80 1459-1462,, 1984.
Santen, LHRH and its Analogues MTP Press Lancaster England pp. 351-364, 1984.
Labrie et al J. Steroid Biochem 19(1) 999-1007, 1984.
Lefebure, et al Prostate, 1982, 3(6) 569-78 Chemical Abstracts vol. 99, 1983, Abstract 1881326.
Levesquo, et al. J. Med. Chem. 1991 34 1624-1630.
Labrie The Prostate 4579-594, 1983.
Keple, et al J. Steroidal Biochem 20(68)1395 1984.
Labrie, et al 7th Int. Congress of Endo. 1984 p. 84.
Lee, et al J. Andrul. 2(6) 293-299, 1981.
Bolis, et al J. Andeol. 4 144-149, 1983.
Habenicht, et al The Prostate 11, 313-326, 1987.
Farnsworth Invest. Urology 6(4) 423-427, 1969.
Groom, et al Biochem. J. 122 125-126, 1971.
Lee, et al Steroids 22, 677-685, 1973.
Moobs, 7th Ann. Meeting of the Endoinno Soc. No. 1410, 1989.
Mobbs et al J. Steroidal Biochem. 19(3) 1279-1290, 1983.
Wagner et al Acta Entocrin. Suppl. 193, 52, 1975.
Voight et al., Endo 1973 92(4), PP. 1216-1222.
Green et al., Nature, 320(13) Mar. 1986, pp. 134-139.
Lubahn et al., Science, 1988 pp. 327-330.
Lubahn et al. Proc. Natl. Acad. Sci. USA 86, 9534-9538, Dec. 1989.
Nericetal, J. Steroidal Biochem., 1957(6), pp. 815-819.
Chang, et al., Biochemistry, 1982, 27-4102-4109.
Gyorhi, et al., J. Steroidal Biochem. 25(3), 355-358, 1986.
Macaulay, et al., J. Steroidal Biochem. 26(5) 535-538, 1987.
Grunwell, et al., Steroids, 27(6), 1976, pp. 759-771.
Chin et al., J. Biol. Chem., 250(19), 1975, pp. 7682-7686.
Auchus Riess, et al., Biochemistry, 1986, 25, 7295-7300.
Schwartz, Organic Synthesis Collective vol. 3, 1950.
Cooke, Jr., Tetrahedron Letters, 22 pp. 1983-1986, 1973.
Gibson, et al., Angew Chem. Int. Ed. 7 (1968) No. 12, pp. 919-930.
Raucher, et al., J. Org. Chem., 1981, 46 3558-3559.
Weiss, et al., Angew Chem. Int. Ed. 12 (1973) No. 10, p. 841.
Bull, et al., Chem. Soc. Chem. Commun. 1986, pp. 451-453.
Wang, et al., Can J. Chem., 65, 2727, 1987.
Salman, et al., J. Steroidal Biochem, 26 383-391, 1987.
Jordan et al., Endocrinology, 124(4), 1989, pp. 1717-1726.
Tora, et al. EMBO 8(7) 1981-1986, 1989.
Doorembos, et al., J. Pharm. Sciences 62(4), 1973, PP. 638-640.
Nayfeh, et al., Steroids 14:3, 1969, PP.269-283.
Doorembos, et al., J. Pharm. Sciences 63(4), 1974, pp. 620-622.
Luthy, et al., J. Steroidal Biochem. 31(5) 845-52, 1988.
Labrie et al., J. Steroid Biochem. 19(1) 999-1007, 1194, 1984.
Beardwell, C. G., Hindley,A. C., Wilkinson, P. M., Todd, I. D., Pibeiro, G. G., Bu'Lock, D. (1983) Trilostane in the treatment of advanced breast cancer. Cancer Chemother. Pharmacol., 10, No. 3, 158-160.
Brooks, J. R., Berman, D., Glitzer, M. S., Gordon, L. R., Primka, R. L., Reynolds , G. F., Rasmusson, G. H. (1982) Effect of a new 5 alpha-reductase inhibitor on size, histologic, characteristics and androgen concentration of the canine prostate. The Prostate, 3, No. 1, 35-44.
Bruchovsky, N., Wilson, J. D. (1968) The conversion of testosterone to 5.alpha.-androstan-17.beta.-ol-3-one by rat prostate in vivo and vitro. J. Biol. Chem., 243, No. 8, 2012-2021. '4n 3104 Coy, D. H., Horvath, A., Nekola, M. V., Coy, E. J., Erchegyi, J., Schally, A. V. (1982) Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position. Endocrinology, 110, 1445-1447.
Debruyne, F. M. J. (1988) The case for LHRH agonists. In: Bailliere's Clinical Oncology International Practice and Research, (Furr, B. J. A., Denis, S., eds). Bailliere's Tindall, pp. 559-570.
Labrie, F., Dupont, A., Belanger, A. and members of the Laval University Prostate Cancer Program (1984) Dramatic response to a new antihormonal treatment for prostate cancer. 7th International Congress of Endocrinology 1984, p. 98.
Lambert, A., Frost, J., Mitchell, R., Robertson,W. R. (1986) On the assessment of the in vivo biopotency and site(s) of action of drug affecting adrenal steroidogenesis. Ann. Clin. biochem., 23, 225-229. '4n 3112 Potts, G. O., Creange, J. E., Handomg, H. R., Schane, H. P. (1978) Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids, 32, No. 2, 257-267.
Robinson, D. T., Earnshaw, R. J., Mitchell, R., Powles, P., Andrews, R. S., Robertson, W. R. (1984) The bioavailability and metabolism of trilostane in normal subjects, a comparative study using high pressure liquid chromatographic and quantitative cytochemical assays. J. Steroid Biochem., 21, No. 5, 601-605.
De Klerk, D. P., Human, H. J., De Klerk, J. N. (1985) The effect of 5.alpha.-androstane-3.alpha.,17.beta.-diol and 17.beta.-estradiol on the adult and immature chacma baboon prostate. The Prostate, 7, 1-12.
Stewart, J. M., Young, J. D., W. H. (1969) In: Solid Phase Peptide Synthesis, Freeman and Co, San Francisco.
Coy, D. H., Vilchez-Martinez, J. S., Coy, E. J., Schally, A. V. (1976) Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J. Med. Chem., 19, No. 3, 423-425.
Wenderoth, U. K., George, F. W., Wilson, J. D. (1983) The effect of a 5.alpha.-reductase inhibition on androgen-mediated growth of the dog prostate. Endocrinology, 113, No. 2, 569-573.
McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Walsh, P. C., Ewing, L. L., Isaacs, J., Stoner, E. (1989) An inhibitor of 5.alpha.-reductase, MK-906, suppresses prostatic dihydrostestosterone in men with benign prostatic hyperplasia. AUA Eighty-fourth Annual Meeting (Dallas, May 7-11). The Journal of Urology, 141, 239A, No. 280.
Stoner, E. (1989) The role of a 5-alpha-reductase inhibitor in BPH. AUA Today, No. Nov./Dec.
Toomey, R. E., Goode, R. L., Petrow, V., Neubauer, B. L. (1989) An in vivo assay for conversion of testosterone (T) to dihydrotestosterone (DHT) by prostatic steroid 5-alpha-reductase and comparison of two inhibitors. 71st Annual Meeting of the Endocrine Society Meeting (Seattle, Jun. 21-24). No 1226.
Labrie, C., Cusan, L., Plante, M., Lapointe,S., Labrie, F. (1987) Analysis of the androgenic acitvity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28, No. 4, 379-384.
Simard, J., Labrie, C., Hubert, J. F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-gly-NH210] luteinizing hormone (LH)-releasing hormone ethylamide of .alpha.-subunit and LH.beta. messenger ribonucleic acid levels in the rat anterior pituitary gland. Molecular Endocr

Affiliated with

Also associated with

Rating

Method of treatment of androgen-related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment of androgen-related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of androgen-related diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1193513